Opium has been used to relieve pain for over 2000 years. In 1806, Serturner described the active principle of opium, morphine, which he called "morphicum". By the latter half of that century, the needle and syringe had been developed and morphine was being used regularly for premedication and postoperative analgesia.
In 1900 Schneiderlein described an anaesthetic technique using 70 mg morphine with scopolamine. Apparently only 70% of the patients required restraining during the surgery but unfortunately a few died so the technique was abandoned! Morphine derivatives became available at around this time. Papaveretum was synthesized in 1901 and hydrocodone bitartrate in 1923. Pethidine, the first synthetic opiate, was synthesized in 1933 and nalorphine, the first antagonist, in 1951.
Janssen pharmaceuticals was founded in 1953 by Dr Paul Janssen in Flanders. Their early studies into opioids led to the development of dextromoramide in 1956. The following year they synthesized phenoperidine, an N-phenylpropyl derivative of norpethidine and in 1960, piritramide, which was the first 4-amino-piperidine derivative. Fentanyl, a 4-anilino-piperidine derivative was synthesized in 1960. Piritramide is a long-acting drug, unsuitable for anaesthesia, but it was an important precursor to the development of other short-acting agents.
With the development of phenoperidine and fentanyl, Janssen was concentrating on improving potency and safety with a view to having more useful analgesics for anaesthesia. Phenoperidine proved to be 50 times more potent than pethidine with an improved safety margin. Fentanyl was even better, with a potency 500 times that of pethidine and a much greater safety margin.
In the first half of the twentieth century, opiates were uncommon in anaesthesia. In 1947, Neff and his colleagues described a technique using nitrous oxide, oxygen and pethidine. Gradually opioids found their way back into the operating theatre and have now become a common part of a balanced anaesthetic.
In 1965, Lowenstein and colleagues at the Massachusetts General began using large doses of morphine (0.5 to 3 mg/kg) and relaxant, without supplementary anaesthesia for cardiac surgery. He reviewed their 2000 cases in 1971 and concluded that the technique was effective and useful, but not without problems. They had few haemodynamic changes and found that they had adequate analgesia in patients with prolonged serious illness. However, during the period of the study, there was an increase in the number of coronary artery grafts, a relatively new population of cardiac surgery patients who did not have low cardiac output. These patients occasionally suffered from very distressing awareness and anaesthetists had begun to add scopolamine to the anaesthetic for these patients.
Fentanyl anaesthesia was first described by Grell and colleagues in 1970. Their experience with 500 patients led them to conclude that "… when the preanaesthetic risk is great, fentanyl and oxygen appear to be an attractive combination. When the technic is adjusted to the patients needs and surgical requirements, fentanyl can provide a simple, safe adjunct to oxygen alone or combined with nitrous oxide in competent hands."
In 1979, Stanley and Webster described high-dose fentanyl anaesthesia for mitral valve replacement in Salt Lake City, Utah. Doses of 74±10 µg/kg of fentanyl were required for the entire operation, with little change in cardiac output, central venous pressure or peripheral vascular resistance. The addition of diazepam was found to significantly alter all parameters and they concluded that "fentanyl-oxygen anaesthesia may be an attractive alternative to morphine anaesthesia in patients with little cardiac reserve".
In the early 1960s Janssen also developed a group of butyrophenones such as haloperidol and dehydrobenzperidol (Droperidol). The combination of a butyrophenone and an opioid was first suggested in 1959 by two Belgian anaesthetists, De Castro and Mundeleer. Various techniques were tried over the next few years and the anaesthetic or "twilight sleep" produced became known as neuroleptanaesthesia. Initially combinations of haloperidol and phenoperidine were used, but there were many serious reactions including circulatory depression, extrapyramidal symptoms and postoperative psychic changes. Further studies using dehydrobenzperidol and fentanyl were more successful. In 1964, Guenther Corssen and his colleagues reviewed some of the early studies on neuroleptanaesthesia. They concluded that it was a useful technique in the elderly and poor risk patients and was also advantageous in cardiac patients. They found recovery to be fast, with postoperative opioids requirements markedly decreased. The greatest problem they found was profound respiratory depression which could usually be overcome by talking to the patient, but occasionally required opiate antagonists. Another disadvantage they noted was muscle wall rigidity which was apparently overcome with suxamethonium! Despite these developments in the pharmacology of opioids, the major problem remained that of prolonged respiratory depression, which limited the use of high-dose opioids to surgery where postoperative ventilation was available. In the mid 1970s, Janssen synthesized a number of potent fentanyl analogues in an attempt to solve this problem. Sufentanil and carfentanil were the first of this group and were extremely potent. Sufentanil is five to ten times more potent that fentanyl and more predictable in its action. Carfentanyl, more potent again, has not been used in humans, but is used extensively for the immobilization of elephants, rhinoceros and other uncooperative large animals. Surprisingly, despite rapid immobilization of the animals, respiratory depression is rarely seen.
In 1982, Paul Janssen stated "There undoubtedly exists an urgent need for a powerful but short-acting analgesic. Alfentanil could be the first compound to fulfill this need." Initial clinical studies were not that successful. Kay and Stephenson reported its use in 1980 and described a number of problems, namely movement, apnoea, difficulty in assisting ventilation and nausea and vomiting. However, they concluded that "alfentanyl will have a useful place in anaesthetic practice and that better clinical results will be obtained with more experience of the drug and better selection of indications for its use."
Alfentanyl is now readily available. Remifentanil, an even shorteracting, potent derivative has recently been released for clinical use and its pharmacokinetics make it suitable for infusions. The place of these shortacting opioids in modern anaesthesia is yet to be fully determined.
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